Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.


TSXV:COV - Post by User

Post by Profitic1on Jul 23, 2020 5:50pm
525 Views
Post# 31310880

Business Outlook

Business OutlookI agree that the company will probably turn things around, but not for a couple of quarters.
Unfortunately, in the short run, there is going to be alot more pain. 
The company burned through over $3M in cash last quarter, and I expect more of the same in the next quarter. On top of this I expect at least a partial writeoff of the $14M goodwill from the Aquaguard acquisition. Did they overpay for that !!!!
At this point, I think another dilutive share financing is inevitable, and I would not be surprised to see the share price hit another 52 week low.

Prof
<< Previous
Bullboard Posts
Next >>